A new recommendation

PBAC recommends listing of adalimumab biosimilar The PBAC has recommended the Authority Required listing of adalimumab (Yuflyma) in the form of 40 mg in 0.4 mL pre-filled syringe and pre-filled pen as a biosimilar brand of Humira. Celltrion Healthcare Australia requested the new PBS listing of the adalimumab biosimilar under the same conditions as its